Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness : 2024 Update
To provide guidance to clinicians about best practices, the Wilderness Medical Society (WMS) convened an expert panel to develop evidence-based guidelines for prevention, diagnosis, and treatment of acute mountain sickness, high altitude cerebral edema, and high altitude pulmonary edema. Recommendations are graded based on the quality of supporting evidence and the balance between the benefits and risks/burdens according to criteria put forth by the American College of Chest Physicians. The guidelines also provide suggested approaches for managing each form of acute altitude illness that incorporate these recommendations as well as recommendations on how to approach high altitude travel following COVID-19 infection. This is an updated version of the original WMS Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness published in Wilderness & Environmental Medicine in 2010 and the subsequently updated WMS Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness published in 2014 and 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Wilderness & environmental medicine - 35(2024), 1_suppl vom: 29. März, Seite 2S-19S |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luks, Andrew M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acetazolamide |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.wem.2023.05.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363261508 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363261508 | ||
| 003 | DE-627 | ||
| 005 | 20240304232002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.wem.2023.05.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM363261508 | ||
| 035 | |a (NLM)37833187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luks, Andrew M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness |b 2024 Update |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To provide guidance to clinicians about best practices, the Wilderness Medical Society (WMS) convened an expert panel to develop evidence-based guidelines for prevention, diagnosis, and treatment of acute mountain sickness, high altitude cerebral edema, and high altitude pulmonary edema. Recommendations are graded based on the quality of supporting evidence and the balance between the benefits and risks/burdens according to criteria put forth by the American College of Chest Physicians. The guidelines also provide suggested approaches for managing each form of acute altitude illness that incorporate these recommendations as well as recommendations on how to approach high altitude travel following COVID-19 infection. This is an updated version of the original WMS Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness published in Wilderness & Environmental Medicine in 2010 and the subsequently updated WMS Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness published in 2014 and 2019 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a High altitude | |
| 650 | 4 | |a acetazolamide | |
| 650 | 4 | |a acute mountain sickness | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a high altitude cerebral edema | |
| 650 | 4 | |a high altitude pulmonary edema | |
| 650 | 4 | |a nifedipine | |
| 700 | 1 | |a Beidleman, Beth A |e verfasserin |4 aut | |
| 700 | 1 | |a Freer, Luanne |e verfasserin |4 aut | |
| 700 | 1 | |a Grissom, Colin K |e verfasserin |4 aut | |
| 700 | 1 | |a Keyes, Linda E |e verfasserin |4 aut | |
| 700 | 1 | |a McIntosh, Scott E |e verfasserin |4 aut | |
| 700 | 1 | |a Rodway, George W |e verfasserin |4 aut | |
| 700 | 1 | |a Schoene, Robert B |e verfasserin |4 aut | |
| 700 | 1 | |a Zafren, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Hackett, Peter H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wilderness & environmental medicine |d 1995 |g 35(2024), 1_suppl vom: 29. März, Seite 2S-19S |w (DE-627)NLM094469377 |x 1545-1534 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:1_suppl |g day:29 |g month:03 |g pages:2S-19S |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.wem.2023.05.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 1_suppl |b 29 |c 03 |h 2S-19S | ||